Noninfectious Intermediate, Posterior, or Panuveitis: Results from the Retrospective, Observational, International EyeCOPE Study.
Corticosteroid disease burden
Disease characteristics
Immunosuppressants
Noninfectious uveitis
Patient-reported outcomes
Journal
Ophthalmology and therapy
ISSN: 2193-8245
Titre abrégé: Ophthalmol Ther
Pays: England
ID NLM: 101634502
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
08
03
2021
accepted:
06
05
2021
pubmed:
13
6
2021
medline:
13
6
2021
entrez:
12
6
2021
Statut:
ppublish
Résumé
The EyeCOPE study characterized noninfectious intermediate posterior, or panuveitis (NIIPPU) before biologic agents were widely available. This retrospective, observational study included adults with NIIPPU attending a routine ophthalmological visit. Data were collected from the study visit and medical records. Of 565 patients, 58.8% were female, and the mean age was 41.3 years; 33.8% had idiopathic uveitis and 45.8% had panuveitis. The median time from symptom onset to diagnosis and treatment was 27.0 and 30.5 days, respectively. Patients received immunosuppressants and systemic/local corticosteroids. Most patients experienced substantial decline in ocular function (mean best corrected visual acuity, 0.4 logMAR). Mean total work productivity impairment among employed patients was 31.0%. Most patients reported ocular complications (70.8%) such as vision loss and cataracts. Despite treatment, most patients with NIIPPU experienced a decline in ocular function and ocular complications. There is an unmet need for additional NIIPPU treatment, such as targeted monoclonal antibodies.
Identifiants
pubmed: 34117983
doi: 10.1007/s40123-021-00351-4
pii: 10.1007/s40123-021-00351-4
pmc: PMC8319263
doi:
Types de publication
Journal Article
Langues
eng
Pagination
565-580Investigateurs
Ayse Cigdem Altan
(AC)
Radgonde Amer
(R)
Matthias Becker
(M)
Florian Balta
(F)
Daniel Branisteanu
(D)
Gustavo Budmann
(G)
Thiago George Cabral Silva
(TGC)
Muge Pinar Cakar Ozdal
(MPC)
Sonja Cekic
(S)
Alina Popa Cherecheanu
(AP)
Carmen Chiotan
(C)
Vivian Cristina Costa Afonso
(VCC)
Cristóbal Couto
(C)
Ciprian Danielescu
(C)
Daniel Vitor de Vasconcelos Santos
(DV)
Assel Doshakanova
(A)
Luis Jose Escaf
(LJ)
Jarmila Fabiánová
(J)
Justus Gerhard Garweg
(JG)
Aida Geamanu
(A)
Tamar Hareuveni
(T)
Jarmila Heissigerová
(J)
Aleksandra Ilic
(A)
Svetlana Jovanovic
(S)
Sanda Jurja
(S)
Sibel Kadayifcilar
(S)
Esra Kardes
(E)
Tea Čaljkušić Mance
(TČ)
Hernando Antonio Muñeton Abadia
(HAM)
Ana Oros
(A)
Hilal Eser Ozturk
(HE)
Yilmaz Ozyazgan
(Y)
Aleksandra Radosavljevic
(A)
Carlos Mario Rangel
(CM)
Ali Osman Saatci
(AO)
Ariel Schlaen
(A)
Maja Vinković
(M)
Nenad Vukojević
(N)
Fatime Nilufer Yalcindag
(FN)
Melike Balikoglu Yilmaz
(MB)
Suzan Guven Yilmaz
(SG)
Oleksandra Zborovska
(O)
Gordana Zlatanovic
(G)
Halil Ateş
(H)
Berna Başarır
(B)
Bora Eldem
(B)
Sandra Garcia
(S)
Patricio Gerardo Schlottmann
(PG)
Juan Guillermo Gaviria
(JG)
Mahmut Kaya
(M)
Sandra Lortz
(S)
Angelica Maria Prada
(AM)
Livia Melcioiu
(L)
Luiz Guilherme Marchesi Mello
(LGM)
Merih Oray
(M)
Sarah Pereira de Freitas Cenachi
(SP)
Emine Temel
(E)
Didar Uçar
(D)
Tamara Mišljenović Vučerić
(TM)
Yuslay Fernández Zamora
(YF)
Cristina Zorila
(C)
Informations de copyright
© 2021. The Author(s).
Références
Am J Ophthalmol. 2005 Sep;140(3):509-16
pubmed: 16196117
Ophthalmology. 2016 Mar;123(3):655-62
pubmed: 26712559
Surv Ophthalmol. 2015 Nov-Dec;60(6):575-89
pubmed: 26164735
Ocul Immunol Inflamm. 2019;27(1):40-50
pubmed: 30015528
Am J Ophthalmol. 2014 Mar;157(3):526-31
pubmed: 24211361
Lancet. 2016 Sep 17;388(10050):1183-92
pubmed: 27542302
Ophthalmology. 2018 Feb;125(2):193-202
pubmed: 28942074
N Engl J Med. 2016 Sep 8;375(10):932-43
pubmed: 27602665
Drugs. 2005;65(4):497-519
pubmed: 15733012
Ophthalmology. 2011 Oct;118(10):1916-26
pubmed: 21840602
Intern Emerg Med. 2019 Aug;14(5):661-675
pubmed: 30684097
Arch Ophthalmol. 2000 Jun;118(6):793-8
pubmed: 10865316
J Ophthalmic Inflamm Infect. 2019 Sep 16;9(1):17
pubmed: 31523783
Clin Ophthalmol. 2015 Aug 25;9:1549-55
pubmed: 26345421
Ophthalmology. 2004 Mar;111(3):491-500; discussion 500
pubmed: 15019324
Curr Rheumatol Rep. 2006 Aug;8(4):260-6
pubmed: 16839504
Arthritis Care Res (Hoboken). 2010 Dec;62(12):1733-8
pubmed: 20665749
J Ophthalmic Inflamm Infect. 2013 Nov 06;3(1):64
pubmed: 24195808
Ocul Immunol Inflamm. 2003 Dec;11(4):287-98
pubmed: 14704900
J Ophthalmic Vis Res. 2018 Apr-Jun;13(2):138-143
pubmed: 29719641
Clin Exp Rheumatol. 2018 Nov-Dec;36(6 Suppl 115):68-73
pubmed: 30582503
Ocul Immunol Inflamm. 2008 Jan-Feb;16(1):1-2
pubmed: 18379933
Jpn J Ophthalmol. 2012 Sep;56(5):432-5
pubmed: 22752308
JAMA. 2017 May 16;317(19):1993-2005
pubmed: 28477440
JAMA Ophthalmol. 2016 Nov 1;134(11):1237-1245
pubmed: 27608193
Br J Ophthalmol. 1996 Apr;80(4):332-6
pubmed: 8703885
Ophthalmology. 2018 Jul;125(7):1075-1087
pubmed: 29429764
Br J Ophthalmol. 2004 Sep;88(9):1159-62
pubmed: 15317708
Health Qual Life Outcomes. 2020 Mar 30;18(1):85
pubmed: 32228619
Orphanet J Rare Dis. 2012 Aug 29;7:57
pubmed: 22932001
Jpn J Ophthalmol. 2007 Jan-Feb;51(1):41-4
pubmed: 17295139
Ocul Immunol Inflamm. 2014 Aug;22(4):249-52
pubmed: 25014114
Ophthalmology. 2014 Mar;121(3):785-96.e3
pubmed: 24359625
Ophthalmology. 2011 Sep;118(9):1892.e3-4
pubmed: 21889663
Int J Dermatol. 2003 Oct;42(10):803-6
pubmed: 14521694
JAMA. 2019 Sep 10;322(10):936-945
pubmed: 31503307